Advocacy News

SITC and ACCC have collaborated on a new webinar aimed at providing further details on the Expanding Access to Cellular and Bispecific Therapy Workshop. This webinar featured expert speakers that provided perspective and thoughts on how to further access to these therapies in the community setting. A full recording of the webinar can be found at this LINK.
0 comments
SITC has provided full comments on a recently released FDA Draft Guidance: "Potency Assurance for Cellular and Gene Therapy Products". Please find the letter in its entirety HERE .
0 comments
SITC has provided meeting coverage of the March 15th ODAC meeting. The coverage includes an overview of the discussion, including representation of the different stakeholder perspectives on each issue, as well as a summary of all recommendations from ODAC. The coverage can be found in its entirety HERE .
0 comments
SITC has provided a letter to ODAC providing insight into the implications of control arm crossover use within clinical trials. The letter also provides support for the use of Progression Free Survival as a viable surrogate endpoint within clinical trials. Please find the letter in its entirety HERE .
0 comments
Thank you to Dr. Ahmad Tarhini from Moffitt Cancer Center and Research Institute for partici pating in SITC’s 2024 Capitol Hill Visits. Dr. Tarhini met with Senator Rubio’s and Representative Castor’s offices to advocate for inclusion of SITC’s FY25 appropriations language aimed at improving Immunotherapy resear ch i n early sta ge diseases. See SITC’s full FY25 language here: SITC FY25 Appropriations ...
0 comments
Thank you to Dr. Nathan Singh from Washington University School of Medicine for participating in SITC’s 2024 Capitol Hill Visits. Dr. Singh met with Senator Hawley ’s and Representative B ush ’s offices to advocate for inclusion of SITC’s FY25 appropriations language aimed at improving Immunotherapy research in early stage diseases. See SITC’s full FY25 language here: SITC FY25 Appropriations Language.pd f
0 comments
Thank you to Dr. Cecilia Yeung from Fred Hutchinson Cancer Research Center for participating in SITC’s 2024 Capitol Hill Visits. Dr. Yeung met with Senator Murray’s, Senator Cantwell’ s and Representative Jayapal ’s offices to advocate for inclusion of SITC’s FY25 appropriations language aimed at improving Immunotherapy research i n early stage diseases. See SITC’s full FY25 language here: SITC FY25 Appropriations Language.pd ...
0 comments
Thank you to Dr. Rimas Orentas from Caring Cross for participating in SITC’s 202 4 Capitol Hill Visits. Dr. Orentas met with Senator Van Hollen's, Senator Cardin's and Representative Trone’s offices to advocate for inclusion of SITC’s FY25 appropriations language aimed at improving Immunotherapy research in early stage diseases. See SITC’s full FY25 language here: SITC FY25 Appropriations Language.pdf
0 comments
SITC and the National Cancer Institute (NCI) are pleased to launch their fourth "SITC-NCI Computational Immuno-oncology Webinar Series" throughout May-December 2024. This year's series will focus specifically on the application of artificial intelligence (AI) across the field of immuno-oncology (IO). Organized by the SITC Big Data and Data Sharing Committee, these nine free-to-attend digital events will help individual research labs to embrace the ...
0 comments
Thank you to Dr. Emily Hopewell from Indiana University for participating in SITC’s 2024 Capitol Hill Visits. Dr. Hopewell met with Senator Young ’s and Representative Baird ’s offices to advocate for inclusion of SITC’s FY25 appropriations language aimed at improving Immunotherapy research in early-stage diseases. See SITC’s full FY25 language here: SITC FY25 Appropriations Language.pdf
0 comments
Thank you to Dr. George Weiner from University of Iowa , Holden Comprehensive Cancer Center for pa rticipating in SITC’s 2024 Capitol Hill Visits. Dr. Weiner met with Senator Ernst’s , Senator Grassley’s and Re presentative Nunn’s offices to advocate for inclusion of SITC’s FY25 appropriations language aimed at improving Immunotherapy research in early-stage diseases. See SITC’s full FY25 language here: SITC ...
0 comments
Thank you to Dr. Michael Hurwitz from Yale Cancer Center for participating in SITC’s 202 4 Capitol Hill Visits. Dr. Hurwitz met with Senator Blumenthal’s and Senator Murphy’s offices to advocate for inclusion of SITC’s FY25 appropriations language aimed at improving Immunotherapy research in early stage diseases. See SITC’s fu ll FY25 language here: SITC FY25 Appropriations Language.pdf
0 comments

SITC on the Hill 2024

SITC is excited to kick off our annual spring Capitol Hill visits! Similar to years past, SITC volunteers will be meeting with their home offices to discuss and advocate for inclusion of specific report language into the FY25 appropriation bills that fund the federal government. Traditionally, SITC has advocated for language directed at the National Cancer Institute (NCI) and Food & Drug Administration (FDA) urging them to prioritize pressing ...
0 comments
SITC has signed on to a letter led by OVAC regarding a top line funding deal. Please find the letter in its entirety HERE .
0 comments
SITC has put together comments on the recently released CMS Proposed OPPS rule. These comments are in alignment with the field and other major cancer focused societies. SITC's full comments can be found HERE .
0 comments
SITC has responded to a recent NCI RFI related to RNA cancer vaccines. SITC's full comments can be found in the letter HERE .
0 comments
SITC has signed on to a Research!America letter related to the approaching debt ceiling deadline and attached funding proposals that support major cuts required to raise the limit. This letter emphasizes the importance of raising the debt ceiling and avoiding cuts to the NIH and other federal funding agencies to ensure continued research funding and progress. Find the letter in its entirety HERE .
0 comments
Recently the National Cancer Institute had issued a Request for Information (RFI) asking the field for ways in which current cancer research could be of possible use against COVID19. The SITC Science and Research Subcommittee led a response letter describing a few ways in which research being done by SITC members could possibly assist. The full text for this letter can be found here and the RFI can be found here.
0 comments
The SITC Policy Committee has a lead a sign on letter focused on support for early career scientist during and after the COVID 19 Pandemic. This letter was cosigned by 8 organizations representing a diverse perspective in the field of cancer. The letter was sent to major federal government funding agencies including the National Institute of Health, National Science Foundation, Department of Defense, and the Department of Veterans Affairs. The full ...
0 comments